CR20110381A - Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 - Google Patents

Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2

Info

Publication number
CR20110381A
CR20110381A CR20110381A CR20110381A CR20110381A CR 20110381 A CR20110381 A CR 20110381A CR 20110381 A CR20110381 A CR 20110381A CR 20110381 A CR20110381 A CR 20110381A CR 20110381 A CR20110381 A CR 20110381A
Authority
CR
Costa Rica
Prior art keywords
ciclohexanol
azetidinil
heteroaril
ccr2
antagonists
Prior art date
Application number
CR20110381A
Other languages
English (en)
Inventor
Xuqing Zhang
Heather Rae Hufnagel
Cuifen Hou
Dana L Johnson
Zhihua Sui
Barry Fegely
David Breslin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110381(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20110381A publication Critical patent/CR20110381A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención comprende los compuestos de la fórmula (I); en donde R1, R2, R3 y R4 son como se definió en la descripción. La invención comprende, además, las composiciones farmacéuticas que comprenden los compuestos de la fórmula (I).
CR20110381A 2008-12-10 2011-07-11 Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 CR20110381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12127208P 2008-12-10 2008-12-10
US16729509P 2009-04-07 2009-04-07

Publications (1)

Publication Number Publication Date
CR20110381A true CR20110381A (es) 2011-11-10

Family

ID=41510894

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110381A CR20110381A (es) 2008-12-10 2011-07-11 Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2

Country Status (28)

Country Link
US (1) US8450304B2 (es)
EP (1) EP2376475B1 (es)
JP (1) JP5782381B2 (es)
KR (1) KR20110094325A (es)
CN (1) CN102317278B (es)
AR (1) AR074583A1 (es)
AU (1) AU2009324723B2 (es)
BR (1) BRPI0923237A2 (es)
CA (1) CA2745969C (es)
CL (1) CL2011001427A1 (es)
CO (1) CO6331470A2 (es)
CR (1) CR20110381A (es)
EA (1) EA018997B1 (es)
EC (1) ECSP11011124A (es)
ES (1) ES2555004T3 (es)
HN (1) HN2011001606A (es)
IL (1) IL213250A0 (es)
MX (1) MX2011006226A (es)
NI (1) NI201100117A (es)
NZ (1) NZ593172A (es)
PA (1) PA8853001A1 (es)
PE (1) PE20110928A1 (es)
SG (1) SG171998A1 (es)
SV (1) SV2011003944A (es)
TW (1) TW201033204A (es)
UY (1) UY32312A (es)
WO (1) WO2010068663A1 (es)
ZA (1) ZA201105056B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745969C (en) 2008-12-10 2017-04-25 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
MX2011010919A (es) * 2009-04-16 2011-11-02 Janssen Pharmaceutica Nv Antagonistas del receptor 2 de citocina quimioatrayente de 4-azetidinil-1-heteroaril-ciclohexano.
NZ595432A (en) * 2009-04-17 2013-12-20 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
KR20120006051A (ko) * 2009-04-17 2012-01-17 얀센 파마슈티카 엔.브이. Ｃｃｒ2의 4-아제티디닐-1-헤테로원자 연결된 사이클로헥산 길항제
TW201211027A (en) * 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
WO2011159854A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
PT3297438T (pt) 2015-05-21 2022-01-25 Chemocentryx Inc Moduladores de ccr2
MA50665A (fr) 2017-09-25 2020-08-05 Chemocentryx Inc Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
CN107793404A (zh) * 2017-11-07 2018-03-13 全椒先奇医药科技有限公司 一种治疗缺血性脑损伤药物组合物及其应用
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057641A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
US6037354A (en) 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
CN1192773C (zh) * 1999-08-04 2005-03-16 帝人株式会社 环胺ccr3拮抗剂
CA2390531A1 (en) 1999-11-08 2001-05-17 Wyeth ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US6706712B2 (en) 2000-12-20 2004-03-16 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
PL376925A1 (pl) 2002-11-27 2006-01-09 Incyte Corporation Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny
UA87449C2 (ru) * 2002-11-27 2009-07-27 Инсайт Корпорейшн Производные 3-аминопиролидина как модуляторы рецепторов хемокина
BRPI0417605B8 (pt) 2003-12-18 2021-05-25 Incyte Corp “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.
EP1802602A1 (en) 2004-09-28 2007-07-04 Janssen Pharmaceutica N.V. Substituted dipiperdine ccr2 antagonists
US20060073592A1 (en) * 2004-10-06 2006-04-06 Wendell Sun Methods of storing tissue matrices
PA8653301A1 (es) * 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
GB0513747D0 (en) 2005-07-06 2005-08-10 Merck Sharp & Dohme Therapeutic compounds
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20070197590A1 (en) 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
CA2745969C (en) 2008-12-10 2017-04-25 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
MX2011010919A (es) * 2009-04-16 2011-11-02 Janssen Pharmaceutica Nv Antagonistas del receptor 2 de citocina quimioatrayente de 4-azetidinil-1-heteroaril-ciclohexano.
NZ595432A (en) * 2009-04-17 2013-12-20 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
KR20120006051A (ko) 2009-04-17 2012-01-17 얀센 파마슈티카 엔.브이. Ｃｃｒ2의 4-아제티디닐-1-헤테로원자 연결된 사이클로헥산 길항제

Also Published As

Publication number Publication date
CA2745969C (en) 2017-04-25
CO6331470A2 (es) 2011-10-20
BRPI0923237A2 (pt) 2019-09-24
UY32312A (es) 2010-06-30
ES2555004T3 (es) 2015-12-28
KR20110094325A (ko) 2011-08-23
CL2011001427A1 (es) 2011-10-21
HN2011001606A (es) 2014-02-03
WO2010068663A1 (en) 2010-06-17
EA018997B1 (ru) 2013-12-30
TW201033204A (en) 2010-09-16
EA201170795A1 (ru) 2011-12-30
JP5782381B2 (ja) 2015-09-24
AU2009324723B2 (en) 2015-07-09
SV2011003944A (es) 2011-07-21
ECSP11011124A (es) 2011-07-29
IL213250A0 (en) 2011-07-31
AR074583A1 (es) 2011-01-26
PA8853001A1 (es) 2010-07-27
CA2745969A1 (en) 2010-06-17
SG171998A1 (en) 2011-07-28
US8450304B2 (en) 2013-05-28
PE20110928A1 (es) 2012-01-05
AU2009324723A1 (en) 2010-06-17
NZ593172A (en) 2013-03-28
EP2376475B1 (en) 2015-09-02
US20100144695A1 (en) 2010-06-10
EP2376475A1 (en) 2011-10-19
CN102317278A (zh) 2012-01-11
CN102317278B (zh) 2016-01-06
MX2011006226A (es) 2011-06-24
JP2012511582A (ja) 2012-05-24
NI201100117A (es) 2012-06-13
ZA201105056B (en) 2012-12-27

Similar Documents

Publication Publication Date Title
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
SV2011003855A (es) Heteroarilos sustituidos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CL2011002825A1 (es) Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CR20110135A (es) INHIBIDORES DE cMET
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
SV2010003617A (es) Fungicidas
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
UY30493A1 (es) Compuestos derivados 5-cloro-1??h,3h-espiro[ 1-benzofuran-2, 4??- piperidin]-1??-ilo sustituidos de los acidos acético y 2-metil- propanoico, composiciones farmacéuticas, procedimientos de preparacion y aplicaciones
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
PA8779801A1 (es) Derivados heterocíclicos sustituidos y su uso farmacéutico y composiciones
PA8855001A1 (es) Monocarbamas
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
SV2011003944A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexano de ccr2
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
UY29486A1 (es) Compuestos utiles en terapia
NI200900078A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.
NI201000023A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica.
EA201170585A1 (ru) Производные изохинолинона в качестве антагонистов nk3
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)